Biotech Values

[ghmm]

ITMN:

I am a long though I have sold some in the 50's lately and will admit to that being a rich valuation for a very simple molecule that has questionable IP to go beyond the Orphan exclusivity and a number of competing analogs in development. I do think it says something for the disease/indication and the potential. A number of people on twitter (I think I saw it first from @lomu_j) pointed out the suspension of this trial.

http://clinicaltrials.gov/ct2/show/NCT02168530

In light of the deal it makes sense why!